A Phase 1 Study of a CDH6-Targeting Antibody-Drug Conjugate in Patients with Advanced Solid Tumors with Evaluation of Inflammatory and Neurological Adverse Events

CONCLUSIONS: Preclinical toxicology did not predict the neurotoxicity observed with HKT288, and a comprehensive assessment performed post hoc did not identify the mechanism of toxicity. The development of further CDH6-targeting ADCs should be pursued with caution.PMID:34515215 | DOI:10.1159/000518549

Source: Cell Research - September 13, 2021 Category: Cytology Authors: Patrick Sch öffski Nicole Concin Cristina Suarez Vivek Subbiah Yuichi Ando Shiling Ruan Joel P Wagner Keith Mansfield Xu Zhu Shizuka Origuchi Sarah DiDominick Carl U Bialucha Jason E Faris Ben Tran Source Type: research